CD276 and diffuse intrinsic pontine glioma: Preliminary results suggest that targeting B7-H3+ tumors, including highly aggressive malignancies such as diffuse intrinsic pontine glioma (DIPG), is feasible, associated with manageable toxicities, and capable of achieving durable tumor regression in some patients6.